Loredana Cifaldi

Has grant

Assistant Professor (RTDb-tenure track)

University of Rome Tor Vergata
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Loredana Cifaldi is an Assistant Professor (RTDb-tenure track) at the University of Rome Tor Vergata, Italy. Her research areas encompass cancer immunotherapy, the effects of polyphenols on endocrine-disrupting chemicals, and the identification of biomarkers in oral squamous cell carcinoma. Recent articles reflect her work on natural killer cells in cancer treatment and the implications of dietary components on cancer progression.

Recent Grants

Grant: Close

Natural Killer cell-based immunotherapy for high-risk Neuroblastoma: pharmacological treatment to efficiently improve the expression of activating ligands.

Open Date: 2014-11-01

Close Date: 2018-10-01

Articles (19)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

The polyphenols Curcumin (CUR) and Resveratrol (RES) are widely described for their antitumoral effects. However, their low bioavailability is a drawback for their use in therapy. The aim of this study was to explore whether CUR and RES, used at a bioavailable concentration, could modulate immune responses while retaining antitumor activity and to determine whether CUR and RES effects on the immune responses of peripheral blood mononuclear cells (PBMCs) and tumor growth inhibition could be improved by their combination. We demonstrate that the low-dose combination of CUR and RES reduced the survival of cancer cell lines but had no effect on the viability of PBMCs. Although following CUR + RES treatment T lymphocytes showed an enhanced activated state, RES counteracted the increased IFN-γ expression induced by CUR in T cells and the polyphenol combination increased IL-10 production by T regulatory cells. On the other hand, the combined treatment enhanced NK cell activity through the up- and downregulation of activating and inhibitory receptors and increased CD68 expression levels on monocytes/macrophages. Overall, our results indicate that the combination of CUR and RES at low doses differentially shapes immune cells while retaining antitumor activity, support the use of this polyphenol combinations in anticancer therapy and suggest its possible application as adjuvant for NK cell-based immunotherapies.

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

Roberto Bei

-

ITALY
View details

Zein Mersini Besharat

Sapienza University of Rome

ITALY
View details

Paolo Palma

Head of Clinical Immunology and Vaccinology Unit

Ospedale Pediatrico Bambino Gesù

ITALY
View details

Silvia Migliaccio

-

ITALY
View details

Enrico De Smaele

Full Professor MED04

Sapienza University of Rome

ITALY
View details

Elisabetta Ferretti

Full Professor

Sapienza University of Rome

ITALY
View details

Daniela Nardozi

Sapienza University of Rome

ITALY
View details

Chiara Focaccetti

-

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.